Embed Size (px)
Citation preview
Dr. David Hampton CEO
Innovative materials to prevent Hospital Acquired Infections
CamStent Ltd Summary
Disruptive Technology: Med-tech material for preventing Hospital Acquired Infections (HAI)
Compelling ROI: NHS hospitals spend £billion+ annually yet 1000’s of lives are lost.
Total addressable market: £375m+ global market for first product.
Superior Performance: Rapid adoption in a market desperately seeking a better solution.
Late-stage opportunity: Can reach market by 2016; has attracted strong interest from large companies.
Seeking: £500k EIS Eligible2
1. Pollack, A. The rising threat of HAI, 2010; 2. House Of Commons, Reducing HAI in Hospitals in England, 2009; 3. Plowman, R. The Socioeconomic Burden Of HAI, 2000
Government Policy:“If the incidence of HAI could be reduced nationally by 10%, the NHS would save £93.1 million each year.
Zero infections may be unachievable, but zero tolerance of avoidable infection is the right ambition.” 2
Healthcare Impact:Afflicts the very old, the very young, weakened immune systems2.
NHS: 300,000 cases per year, over 10,000 deaths2 (US: 1.7m / 99k1.)
Hospital stays are 2.5 times longer, costs three times higher3.
3
The Healthcare Burden of HAI
4
CamStent creates antimicrobial catheters
An innovative medical coating
- Drug-free: Will not promote antibiotic resistance.
- Inexpensive: Applied as a supplemental manufacturing step.
5
- Forms a smooth stable surface.
- Strong, flexible adhesion.
- Targets the cause of Catheter Acquired Infections.
- Prevents bacterial colonisation.
1 Hook, AL"Combinatorial discovery of polymers resistant to bacterial attachment." Nature biotechnology (2012).
80% reduction in colonisation by E. coli and P. mirabilis for at least 10 days.
Confocal microscopy data: Perfectus Biomed Ltd. Bacteria appear red in the lower panels.
An effective antimicrobial
6
Outperforms silver alternative
Bacterial surface coverage on uncoated and market-leading Bardex coated catheter vs. CamStent coated catheter, after 10 days incubation.
Confocal microscopy data: A. Hook, unpublished
Next step to market:
Pilot production
and Clinical validation.
7
Broad intellectual property
8
Filing Name Date Source
GB2448153
Coated Medical Devices
4/4/2007
CamStent
GB1107416.8
Novel polymers which resist bacterial attachment
4/5/2011
Univ of Nottingham*
GB1200388.5
Derivatised calixarenes as coatings for implantable medical devices
11/1/2012
CamStent
• Exclusive worldwide license for urology.• ‘per/unit royalty on CamStent revenues.
Dr. David Hampton, CEO Medtronic director, new product research and deployment.
CFO and Board of Directors Finance / NEDs with deep corporate and industry expertise.
Full-Time Development Team•Alan Collins (Production) Princ. chemist, Dow Corning•Iain Barlow (Chemistry) Incubator facility•Helga Mikkelsen (Microbiology) Babraham laboratory
9
An experienced organisation
Moving towards market entry
Pilot facility in operation: Making dip-coated prototypes. Preparing for CE Mark Approval
Clinical trial plan approved: University of Southampton. Prevent colonisation, reduce infections.
Today’s Position
10
Investment History
2008 - 2010Prizes / EEDA grant/ Founders
£ 110k
Q1 2011 Equity Round 1 £ 350kQ4 2011 TSB grant £ 250kQ1 2012 Equity Round 2 £ 510k
TOTAL FUNDING£1,220k
11
Use of Funds
Round 3 – £500k raise for pilot production, clinical trials, and CE Mark regulatory testing.
12
In-market revenues
13
Revenue Forecast
14
Future opportunities Attractive target for catheter manufacturers, materials suppliers, specialist coatings companies.
Major (>2bn$ mkt cap) companies have expressed interest.
Grow the business with superior coating products resisting bacterial, blood, and protein adhesion.
Leverage existing team, facilities, and IP.
15
Summary
Market Medical Devices Coating prevents bacterial colonisation and costly infections
Stage Pre-market Ready for clinical trial One year to product introduction
Patents One issued, one pending, one licensed
Share offer £500,000 EIS Eligible
Objectives • Secure clinical evidence• Achieve CE Mark readiness• Prepare follow-on products
16
Dr. David Hampton CEO
John Mayfield CFO
Innovative materials to prevent Hospital Acquired Infections
+44 (0) 7860 559492
Outline of CamStent Production Process
26 Jun 2014 Confidential
